Trial Profile
Association of expression of topoisomerase-II and efficacy of amrubicin in patients with advanced non-small cell lung cancer: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer